For genes included in calculating PRSgene, we performed gene ontology enrichment analysis using PANTHER (released 2021-01-24) [46] implemented in the Gene Ontology (GO) Resource (http://geneontology.org/, released 2021-08-18). We focused on GO Biological Processes (GOBPs). We also used Functional Mapping and Annotation of Genome-Wide Association Studies (FUMA) [47] to test whether these genes were enriched in Differentially Expressed Gene (DEG) sets calculated using 54 tissues from The Genotype-Tissue Expression (GTEx V8) project [48]. We searched the GWAS catalog (https://www.ebi.ac.uk/gwas/. accessed: 2021-10-11) [49] to check whether these genes had been previously implicated in GWAS of AUD-related phenotypes. Lastly, we checked whether these genes could be potential drug targets by searching the gene list for targets of the FDA-approved drugs as well as those in current clinical trial investigations, compiled by Wang et al. [24] derived from the Informa Pharmaprojects database (https://pharmaintelligence.informa.com/products-and-services/data-and-analysis/pharmaprojects).
